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Abstract
Lethal mutagenesis, or virus extinction produced by enhanced mutation rates, is under investigation as an antiviral strategy
that aims at counteracting the adaptive capacity of viral quasispecies, and avoiding selection of antiviral-escape mutants. To
explore lethal mutagenesis of hepatitis C virus (HCV), it is important to establish whether ribavirin, the purine nucleoside
analogue used in anti-HCV therapy, acts as a mutagenic agent during virus replication in cell culture. Here we report the
effect of ribavirin during serial passages of HCV in human hepatoma Huh-7.5 cells, regarding viral progeny production and
complexity of mutant spectra. Ribavirin produced an increase of mutant spectrum complexity and of the transition types
associated with ribavirin mutagenesis, resulting in HCV extinction. Ribavirin-mediated depletion of intracellular GTP was not
the major contributory factor to mutagenesis since mycophenolic acid evoked a similar decrease in GTP without an increase
in mutant spectrum complexity. The intracellular concentration of the other nucleoside-triphosphates was elevated as a
result of ribavirin treatment. Mycophenolic acid extinguished HCV without an intervening mutagenic activity. Ribavirin-
mediated, but not mycophenolic acid-mediated, extinction of HCV occurred via a decrease of specific infectivity, a feature
typical of lethal mutagenesis. We discuss some possibilities to explain disparate results on ribavirin mutagenesis of HCV.
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Introduction
Hepatitis C virus (HCV) infections affect about 180 million
people worldwide, and an estimated 75% of newly infected
patients progress towards a chronic infection, which constitutes a
risk for severe liver diseases such as cirrhosis and hepatocarcinoma
[1–4]. HCV is an hepacivirus of the Flaviviridae family that displays
the error-prone replication and quasispecies dynamics typical of
RNA viruses [3,5–7]. No vaccine is available to prevent HCV
infections or disease, and the current standard of care (SOC)
treatment consists of the combination of pegylated interferon-a
(IFN-a) and the purine nucleoside analogue ribavirin (1-b-D-
ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) (Rib) (IFN-
a+Rib). However, on average only about 60% of the chronically
infected patients show a sustained virological response that results
in virus clearance [8–11]. The mechanism of anti-HCV activity of
IFN-a+Rib and the reasons for treatment failure are largely
unknown. HCV evolving in hepatoma cells in culture can find
multiple mutation pathways to acquire resistance to IFN-a, and
resistant HCV populations display decreased sensitivity to a IFN-
a+Rib combination treatment [12]. New therapeutic options have
been opened with the development of directly acting antiviral
agents (DAAs), but it is not clear which new combinations will be
the most effective, although inclusion of Rib appears to be
important [13–17].
The prior experience gained with the treatment of infections by
highly variable RNA viruses that exhibit quasispecies dynamics, in
particular human immunodeficiency virus type 1 (HIV-1),
anticipates that HCV variants with different degrees of resistance
to one or multiple anti-HCV inhibitors will be selected with high
probability in the course of the new treatments [18–25]. Rapid
selection of antiviral-resistant mutants is a direct consequence of
quasispecies dynamics and one of the main reasons that impulsed
research on a new antiviral strategy termed virus entry into error
catastrophe or lethal mutagenesis. It is based on one of the
corollaries of quasispecies theory that asserts that a sufficient
increase of error rate during genome replication should result in
the loss of the information conveyed by the replicative system
[26,27]. In agreement with these and other theoretical treatments
[28–34], virus extinction associated with enhanced mutagenesis
has been documented with several RNA viruses in cell culture and
in vivo [35–54]. Rib is one of the mutagenic agents that are
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currently used in the investigations on lethal mutagenesis because
it has been licensed for human use for several decades, and proven
to be mutagenic first for poliovirus (PV) [37,55,56], and then for
several other RNA viruses [35,40,48,49,51,57–62], but not for
others [63–65]. It is not clear whether Rib exerts its anti-HCV
activity through mutagenesis or other mechanisms [58,66–77].
Alternative antiviral mechanisms of Rib are: (i) immunomodula-
tion and enhancement of the Th1 antiviral immune response
[78,79]; (ii) up-regulation of genes involved in IFN signaling
[80,81]; (iii) inhibition of viral RNA-dependent RNA polymerases
(RdRps) [82–87]; (iv) depletion of intracellular GTP levels [88];
and (v) inhibition of mRNA cap formation [89].
While some studies in cell culture have suggested a mutagenic
activity of Rib on HCV [58,73,76,90–92], other investigations
have failed to provide evidence of Rib mutagenesis [93,94].
Elucidation of the anti-HCV mechanism of Rib is highly relevant
because it may influence the design of antiviral protocols. Recent
model studies with different virus-host systems have indicated that
when a mutagenic agent participates in therapy, a sequential
administration of an inhibitor first, followed by a mutagenic agent
may be more effective than the corresponding combination
therapy to achieve virus extinction [49,95–97]. The advantage
of a sequential administration depends on the concentrations of
mutagen and inhibitor used, and it requires that one of the drugs
used for therapy acts as a mutagenic agent [95–97]. Thus, with the
advent of DAAs, it is important to clarify the mechanism of Rib
activity against HCV to compare the effectiveness of alternative
antiviral protocols first in cell culture and then in animal models
and clinical trials.
The development of systems which allow infection of cultured
cells with HCV particles containing the entire viral genome [98–
100] permits addressing HCV evolution over extended periods of
time (serial infections) in the presence of antiviral agents, without
possible confounding effects derived from host cell evolution [12].
Here we study the effect of exposure of HCV in cell culture
[12,101] to several drugs or drug combinations in a multiple
passage design, as depicted in Fig. 1. The results indicate that Rib
is mutagenic for HCVp0, and that Rib-mediated, but not
mycophenolic acid-mediated, HCV extinction displays the attri-
butes of lethal mutagenesis.
Results
Cytotoxicity and inhibitory activity of ribavirin and
mycophenolic acid
To determine cytotoxicity of the drugs (concentration that
reduces cell viability by 50%, CC50) used in the present study,
Huh-7.5 reporter cells were incubated with increasing concentra-
tions of Rib or mycophenolic acid and cell viability determined
after 72 h of treatment. To quantify the inhibition of infectious
HCV progeny production (drug concentration that produces a
50% decrease in progeny production, IC50), Huh-7.5 cells were
infected with HCVp0 at a multiplicity of infection (MOI) of 0.2–
0.5 TCID50/cell in the presence of increasing concentrations of
the drugs and infectious progeny production measured. From the
data, CC50 and IC50 values were calculated (Fig. 2), that yielded a
therapeutic index (TI) (CC50/IC50) of 12.8, and .212.8 for Rib
and mycophenolic acid, respectively. These values served as guide
for the choice of drug concentrations in the experiments.
Influence of infection conditions on the response of HCV
to ribavirin treatment during replication in human
hepatoma cells
The parental HCVp0 virus [12,101] was prepared as described in
Materials and Methods, and used to investigate the response of
HCV to Rib. HCVp0 was subjected to 10 serial passages in Huh-7.5
cells using either high (1–2 TCID50/cell) or low (0.1–0.2 TCID50/
cell) initial MOI, in the absence or presence of different Rib
concentrations. The results show a consistent decay of progeny
infectivity and of intracellular HCV RNA as a result of Rib
treatment, while a sustained viral replication was observed in the
absence of Rib (Fig. 3). An exception was the decreased but
continued replication of HCV in the presence of 50 mM Rib in the
infection at high MOI (Fig. 3a). In all other cases, infectivity and viral
RNA decreased to levels below the corresponding limits of detection
by passages 3 to 9 (Fig. 3a, b). Decay of infectivity in the cell culture
supernatant always preceded decay of intracellular viral RNA, an
observation previously made during mutagenesis-based extinction
of lymphocytic choriomeningitis virus (LCMV) [42].
In previous studies on lethal mutagenesis of foot-and-mouth
disease virus (FMDV) and LCMV we defined a double criterion to
consider the virus extinct: (i) absence of infectivity following three
Figure 1. Scheme of serial hepatitis C virus passages performed in the present study. The initial clonal population HCVcc (filled square)
was prepared by transcription of plasmid Jc1 FLAG (p7-nsGluc2A) (RNA HCVcc) and electroporation into Lunet cells, as described in Materials and
Methods. The amplified virus HCVp0 was subjected to serial passages in the presence of different drugs or drug combinations, as indicated; uncloned
populations are depicted as empty circles. Infections with the replication-negative HCV mutant GNN were carried out in parallel (not shown in this
scheme). The multiplicity of infection (MOI), drug concentrations, and the various analyses performed with different HCV populations are detailed in
the corresponding experiments.
doi:10.1371/journal.pone.0071039.g001
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blind passages of the undiluted cell culture supernatant in the host
cells in the absence of any drug, and (ii) absence of intracellular
viral RNA using a highly sensitive RT-PCR amplification protocol
[47,52,57]. When these criteria were applied to the Rib-treated
HCV populations, no infectivity could be rescued when superna-
tants devoid of detectable infectivity were further passaged in the
absence of Rib. However, some residual HCV RNA persisted as
judged by an amplification band (above the background level of
the negative control) even when the treatment was extended to 15
passages (Fig. 3b).
Mutant spectrum complexity in hepatitis C virus
populations passaged in the absence or presence of
ribavirin
To examine whether the decrease of infectivity upon HCV
replication in the presence of Rib was accompanied with a
mutagenic activity of Rib, the mutant spectrum complexity at the
E2-, NS5A- and NS5B-coding regions (chosen because they
encode structural and non-structural proteins displaying different
degrees of conservation) of several HCV populations was
evaluated (Table 1). NS5A and NS5B of populations passaged
three times at low MOI in the presence of Rib underwent a
significant increase of mutation frequency (1.4- to 3.0-fold with
50 mM Rib, and 1.6- to 4.8-fold with 100 mM Rib), relative to the
population passaged in absence of Rib (p,0.05 to p,0.0005; x2
test). Statistically significant increases of nucleotide diversity were
also observed for increasing Rib concentrations (NS5A p,0.004;
NS5B p,0.04 and p,0.005; Permutation test) (Table 1). Riba-
virin induces preferentially GRA and CRU transitions in HCV
and other RNA viruses [35,56,57,77,102]. While the percentage of
transitions relative to the total number of mutations did not vary as
a result of Rib treatment (79.1%, 75.6% and 79.4% in the absence
and presence of 50 and 100 mM Rib, respectively), the
corresponding percentage of [(GRA)+(CRU)] transitions in-
creased from 32.5% in the absence of Rib to 51.7% and 57.7%
in the presence of 50 and 100 mM Rib, respectively, reflected also
in an increase of the [(GRA)+(CRU)]/[(ARG)]+[(URC)] ratio
(Fig. 4a). The mutational bias reinforces the conclusion that Rib
acts as a HCV mutagen. [The amino acid substitutions and their
score according to the PAM 250 substitution matrix [103] – a
measure of their probability of occurrence – are listed in
Tables S1, S2 and S3.
To further investigate the mutagenic activity of Rib, mutant
spectrum complexity of the NS5A-coding region in the popula-
tions passaged at a MOI of 1 to 2 TCID50/cell was investigated by
molecular cloning and Sanger sequencing, and ultra-deep
pyrosequencing. The analysis of molecular clones (Table 2)
indicates a significant increase of mutation frequency (2.5- fold
with 75 mM Rib, and 2.8-fold with 100 mM Rib), relative to the
population passaged in the absence of Rib (p,0.05 and p,0.005,
respectively; x2 test). A significant increase of nucleotide diversity
was observed in the NS5A-coding region for populations treated
with increasing concentrations of Rib (passage 4 populations,
p,0.0017; Permutation test). Concerning the distribution of
mutation types, again while the percentage of transitions relative
to the total number of mutations did not vary as a result of Rib
treatment (82.1%, 76.6% and 88.0% in the absence and presence
of 75 mM and 100 mM Rib, respectively), the corresponding
percentage of [(GRA)+(CRU)] transitions relative to the total
number of mutations increased significantly [from 14.3% in the
absence of Rib to 59.5% and 68.0% in the presence of 75 and
100 mM Rib, respectively (p,0.05 and p,0.01, respectively; x2
Figure 2. Quantification of cytotoxicity for Huh-7.5 cells and inhibition of HCV infectious progeny production by ribavirin and
mycophenolic acid. Determinations of cytotoxic concentration 50 (CC50) (left panels) and the drug concentration required for 50% inhibition, or
inhibitory concentration 50 (IC50) (right panels) were carried out in triplicate. Values and standard deviations were calculated using the program
Sigma Plot. Experimental conditions for cell growth, HCV infection, determination of cell viability and HCV infectivity are described in Materials and
Methods.
doi:10.1371/journal.pone.0071039.g002
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test)] (Table 2 and Fig. 4b). The percentage of nonsynonymous
mutations, the amino acid substitutions, and their probability of
occurrence are given in Table S4. There is a very clear agreement
between the mutant spectrum analyses of populations resulting
from HCV infections in the presence of Rib at high and low MOI,
indicating that Rib is mutagenic for HCVp0 replicating in
hepatoma cells.
An alternative sampling method of viral mutant spectra is
provided by ultra-deep pyrosequencing (UDPS). We chose to
determine the number of haplotypes and frequency of different
transitions in six amplicons that spanned the entire NS5A-coding
region of the HCVcc populations passaged 4 times in Huh-7.5
cells either in the absence or presence of 75 mM Rib. The results
(Table 3, Fig. 4c and Table S5) indicate an increase in the number
of different mutations, polymorphic sites, haplotypes and propor-
tion of [(GRA)+(CRU)] in the populations passaged in the
presence of Rib. Thus, UDPS also indicates a mutagenic activity
of Rib on HCV.
The effect of guanosine on the inhibitory and mutagenic
activity of ribavirin. Alteration of nucleotide pools
Ribavirin is metabolized by cellular enzymes to produce the
mono- di- and tri-phosphate nucleotide derivatives (RMP, RDP,
RTP, respectively) [88,104]. RMP is a competitive inhibitor of
inosine monophosphate dehydrogenase (IMPDH), resulting in
reduced intracellular GTP levels [88,105,106]. Guanosine can
reverse the inhibitory effect of RMP on IMPDH [35,60,104,107].
Therefore, we examined the effect of guanosine alone and
guanosine plus Rib on HCV multiplication. Replication of
HCVp0 in the presence of 200 mM guanosine resulted in a 10-
to 100-fold decrease in HCV infectious progeny production and
intracellular viral RNA, and the decrease diminished with passage
number (Fig. 5a). Guanosine partially compensated the inhibition
exerted by 50 mM Rib, but only minimally the inhibition by
100 mM Rib. In all cases the presence of guanosine delayed the
Rib-mediated extinction of HCV. Only a minor reduction of
mutant spectrum complexity (that did not reach statistical
significance) was observed in the presence of guanosine at the
two Rib concentrations tested (Table 4). Likewise, the Rib-
mediated increase of nucleotide diversity and [(GRA)+(CRU)]/
[(ARG)+(URC)] ratio diminished only modestly in the presence
of guanosine (Table 4 and Fig. 4d; the amino acid substitutions are
listed in Table S6). To determine the effect of Rib treatment on
the GTP level, the intracellular amount of GTP and RTP was
measured in Huh-7.5 reporter cells at 8 h and 72 h after treatment
with 50 mM and 100 mM Rib. The results (Fig. 5b) show a 3.0- to
8.5-fold reduction in the intracellular concentration of GTP. RTP
reached maximum levels of 0.07 fmol/cell at 72 h of treatment
with 100 mM Rib. In contrast to GTP, all other nucleotides
increased their concentration as a result of Rib treatment, with
maximum increases for the pyrimidine nucleotides (4.2-fold for
UTP and 3.4-fold for CTP); the increase was partially reversed by
the presence of guanosine (Fig. 5c). Thus, addition of guanosine to
Huh-7.5 reporter cells did not restore the GTP depletion resulting
from Rib addition. In view of these results, it was interesting to
examine the effect of mycophenolic acid on HCV progeny
production and mutagenesis.
The effect of mycophenolic acid on hepatitis C virus
progeny production and nucleotide pools
Mycophenolic acid is an inhibitor of IMPDH, which contrary to
RTP or GTP cannot be incorporated into RNA [105,108–110].
To explore whether depletion of GTP by itself (in the absence of
an added mutagenic agent) could jeopardize infectious HCV
progeny production, serial passages were carried out in the
presence of mycophenolic acid in the absence or presence of
guanosine. Mycophenolic acid produced a dramatic inhibition of
HCV production that resulted in HCV extinction (Fig. 6a).
Significantly, in the transition towards extinction, loss of infectivity
preceded loss of intracellular viral RNA. The inhibitory effects of
mycophenolic acid was almost fully reversed by guanosine, a
reversal that was not observed previously with other hepatoma
cells or HCV replicons [93,111]. Depletion of GTP by
mycophenolic acid was comparable to that produced by Rib,
and also not reversed by guanosine addition, whereas the increase
in the concentration of the other standard nucleotides was 1.5- to
4-fold lower (compare Figs. 5c and 6b). Passages in the presence of
mycophenolic acid did not result in any significant increase of
mutant spectrum complexity or mutational bias (Fig. 4d and
Tables 5 and S7). Mycophenolic acid in the 2.5–5 mM range drove
viral infectivity and RNA below the limit of detection. Further-
more, no HCV RNA could be amplified from the cell culture
supernatant, using the sensitive RT-PCR protocol to diagnose
extinction (Fig. 6a). The results suggest that depletion of GTP
contributes to inhibition of HCV progeny production, without
involving a mutagenic activity (see Discussion). The inhibitory
effect of mycophenolic acid can drive HCV to extinction.
Probing features of lethal mutagenesis in the extinction
of hepatitis C virus by ribavirin and mycophenolic acid
Mutagenesis-driven extinction of FMDV and LCMV occurred
with 102-to 103-fold decreases of specific infectivity (the ratio
between viral infectivity and the amount of genomic viral RNA)
and without any detectable variation in the consensus genomic
nucleotide sequence [42,112,113]. These features are a hallmark
of virus extinction by lethal mutagenesis [reviewed in [114,115]].
Extinction by Rib occurred with a 5-fold to 23-fold decrease of
specific infectivity, as quantified by infectivity and viral RNA in
samples of the cell culture supernatants (Fig. 7a). In contrast, no
variation in specific infectivity was observed during mycophenolic
acid-mediated extinction (Fig. 7b). In both cases the consensus
sequence remained invariant. Thus, Rib-mediated, but not
Figure 3. The effect of ribavirin on infectious HCV progeny production and intracellular HCV RNA. (a) Huh-7.5 reporter cells were
infected with HCVp0 at a MOI of 1–2 TCID50/cell (10
5 Huh-7.5 reporter cells infected with 16105 to 26105 TCID50 of HCVp0), in the absence or
presence of the Rib concentrations indicated in the upper box. Infections with HCV GNN were carried out in parallel (negative control). The progeny
from each infection was used to infect fresh cells, as described in Materials and Methods. Virus infectivity was determined in the cell culture
supernatant (left panel), and intracellular viral RNA measured by quantitative RT-PCR (right panel). The discontinuous line parallel to the abscissa
indicates the limit of detection of infectivity and viral RNA. Below, RT-PCR amplification bands using a highly sensitive HCV-specific amplification
protocol that yields a 539 bp fragment, using as template total intracellular RNA from the infection series and passage numbers indicated at the top
of the corresponding lanes; +, 2: presence or absence of amplification band; the position of DNA size markers is indicated on the left. (b) Same as in
(a) but with infections carried out at an initial MOI of 0.1 – 0.2 TCID50/cell, using two different protocols: 4610
6 Huh-7.5 reporter cells infected with
46105 to 86105 TCID50 of HCVp0 (duplicate assays, named 1 and 2, left panels), and 4610
5 Huh-7.5 reporter cells infected with 46104 to 86104
TCID50 of HCVp0 (duplicate assays, named 1 and 2, right panels). Symbols and RT-PCR amplification bands shown at the bottom were obtained as is
explained in part (a). Procedures are described in Materials and Methods.
doi:10.1371/journal.pone.0071039.g003
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mycophenolic acid-mediated, HCV extinction displayed the
hallmarks of lethal mutagenesis. In conclusion, we have provided
evidence that Rib alters the mutant spectrum composition of HCV
quasispecies replicating in hepatoma cells in a manner compatible
with a mutagenic activity of Rib.
Discussion
Lethal mutagenesis is gradually finding its way as a potential
antiviral therapy with reduced probability of selection of escape
mutants [54,116,117], and with prospects of applying the same
principles to anti-cancer therapy [118–120]. The mechanism by
which Rib exerts its antiviral activity is still a debated issue since
multiple, unrelated modes of action have been observed with
different viruses [59,106,121], and more than one mechanism may
be operating on a given virus. Recent studies of antiviral designs
based on lethal mutagenesis render important a clarification of
whether mutagenesis of the viral genome occurs in the course of an
antiviral treatment. Indeed, a potential advantage of a sequential
inhibitor-mutagen administration over the corresponding combi-
nation, necessitates that a mutagenic agent be part of the therapy
[95–97]. We are currently extending to HCV our previous
approach of testing the efficacy of alternative administration
protocols [reviewed in [114]]. Rib is ideally suited for the
investigations on lethal mutagenesis of HCV because it is a
component of SOC treatment. In the present investigation, the
mutagenic activity of Rib on HCV replicating in Huh-7.5 reporter
cells has been documented by statistically significant increases of
mutant spectrum complexity and an increase of GRA and CRU
transitions. In the NS5A-coding region, UDPS identified a total of
38 and 127 different mutations in the populations passaged in the
absence and presence of Rib, respectively. The corresponding
numbers identified by molecular cloning and Sanger sequencing
were 28 and 46, respectively. Of the total number of different
mutations scored, only 5 and 12, in the absence and presence of
Rib, respectively, were common to Sanger sequencing and UDPS
(Tables S4 and S5). Thus, despite sampling different sequences,
both procedures provide evidence of a mutagenic activity of Rib
on HCV. Other activities of Rib in Huh-7.5 cells may contribute
to the anti-HCV action of Rib. It must be indicated, however, that
solely a change in mutant spectrum composition does not provide
evidence of a mutagenic activity, since a drug may alter the
relative fitness of viral subpopulations. This might cause a
variation in the broadness of the mutant spectrum. In our case,
however, it seems unlikely that such mutant spectrum reorgani-
zation would lead to a mutational bias in favor of GRA and CRU
Figure 4. Matrix of nucleotide substitutions in the mutant spectrum of hepatitis C virus populations passaged in the absence or
presence of drugs or drug combinations. Mutation types (from nucleotides written vertically to those written horizontally) are counted for the
individual components of the mutant spectrum relative to the corresponding consensus sequence of the population. Drug concentrations present
during HCV passages are written at the top of each matrix (abbreviated as: ribavirin, Rib; mycophenolic acid, MPA; guanosine, Gua). When Rib was
present, the types of mutations expected from Rib mutagenesis are highlighted in red, and their ratio to the other transition types is boxed below
each matrix. (a) HCV populations subjected to three passages at an initial MOI of 0.1–0.2 TCID50/cell; the populations are those described in Fig. 3b
and Tables 1, S1, S2 and S3. (b) HCV populations subjected to four or five passages at an initial MOI of 1–2 TCID50/cell; the populations are those
described in Fig. 3a and Tables 2 and S4. (c) Same as (b) but for HCV populations at passage 4 analyzed by UDPS, including mutations that are
repeated in different amplicons; the populations are those described in Tables 3 and S5. (d) HCV populations subjected to three passages at a MOI of
0.1–0.2 TCID50/cell in the presence of Rib or MPA with or without Gua; the populations are those described in Figs. 5 and 6, and Tables 4, 5, S6 and
S7. Procedures are described in Materials and Methods.
doi:10.1371/journal.pone.0071039.g004
Table 1. Quasispecies analysis of HCVp0 populations passaged in the absence or presence of ribavirina.
Genomic regionb
Ribavirin
conc. (mM)a
Number of nt analyzed
(clones/haplotypes)c
Mutation
frequencyd
Nucleotide
diversity e
p. 103 (95% CI)
0 15,122 (15/9) 9.361024 1.11 (0.73–1.58)
E2 (nt 1490–2590) 50 18,860 (17/14) 1.361023 1.49 (1.15–2.01)
100 20,657 (21/16) 1.561023 1.74 (1.33–2.51)
0 29,704 (22/18) 7.761024 1.16 (0.93–1.51)
NS5A (nt 6269–7666) 50 23,766 (17/17) 1.461023 1.54 (1.16–2.11)
100 21,396 (20/20) 2.161023 2.43 (1.99–3.44)
0 22,691 (18, 10/5, 3) 2.561024 0.74 (0.53–1.03)/
0.23 (0.11–0.56)
NS5B (nt 7667–8442/
8443–9442)
50 37,862 (24, 22/17, 9) 7.661024 1.60 (1.22–2.10)/
0.50 (0.26–0.87)
100 16,676 (12, 11/7, 8) 1.261023 1.25 (0.79–1.79)/
1.39 (0.74–2.30)
aThe population analyzed correspond to passage 3 of the infections at an initial MOI of 0.1 to 0.2 TCID50/cell described in Fig. 3b.
bThe HCV genome residue numbering corresponds to the JFH-1 genome (accession number #AB047639). The NS5B-coding region was covered by two overlapping
amplifications.
cThe parenthesis indicates the number of clones analyzed, followed by the number of haplotypes (number of different RNA sequences); some clones did not contain the
full length sequence; when the alignment of the sequenced region was correct such clones were entered in the calculation.
dAverage number of mutations per nucleotide relative to the corresponding consensus sequence. Mutation types are summarized in Fig. 4a and their position in the
HCV genome and deduced amino acid substitutions are given in Tables S1, S2 and S3.
eThe calculation of nucleotide diversity (p) and 95% confidence interval (CI) is explained in Materials and Methods.
doi:10.1371/journal.pone.0071039.t001
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transitions in the absence of a mutagenic activity associated with
Rib treatment.
Depletion of intracellular GTP levels does not account for the
majority of Rib-mediated mutagenesis, since no mutagenesis was
observed under the same depletion as a result of treatment with
mycophenolic acid. This immunosuppressant and some of its
prodrugs have proven effective as inhibitors of HCV multiplica-
tion in cell culture and in vivo [93,111,122,123]. Significantly,
extinction by the non-mutagenic mycophenolic acid did not alter
the specific infectivity of HCV and, with our quantification
procedures infectivity was still detectable when extracellular HCV
RNA was not. This is in contrast to the decrease in specific
infectivity associated with Rib-mediated extinction, a hallmark of
lethal mutagenesis [35,42,57,61,62,97,113] (Fig. 7).
It is not clear whether the inhibition of HCV progeny
production by Rib is directly linked to its mutagenic activity or
to some other effect on the virus or the host cell, independent of its
mutagenic activity. The difference in compensatory activity of
guanosine on the inhibition produced by 50 mM and 100 mM Rib
does not appear to be related to variations in intracellular GTP.
Rather, Rib produced a considerable increase in intracellular
ATP, CTP and UTP that was only partially compensated by
guanosine addition. Concentrations of mycophenolic acid that
depleted GTP to a similar extent than Rib led to a less accentuated
increase of ATP, CTP and UTP. Thus, imbalances in the levels of
the standard nucleotides might contribute to the inhibition
produced by Rib. Modifications of hepatocyte gene transcription
may affect completion of the virus life cycle [124]. ATP – which
underwent a 2-fold higher increase upon treatment with Rib than
with mycophenolic acid (Figs. 5 and 6) – is recruited in HCV-
infected hepatocytes where it co-localizes with non-structural
HCV proteins in cytoplasmic structures; the ATP concentration is
about 5-fold higher at these sites than elsewhere in the cell [125].
ATP levels may modify the activity of the ATP-dependent
Table 2. Quasispecies analysis of NS5A genomic residues of HCVp0 populations passaged in the absence or presence of ribavirina.
Ribavirin
conc. (mM)a
Passage
number
Number of nt analyzed
(clones/haplotypes)b
Mutation
frequencyc
Nucleotide
diversityc
p. 103 (95% CI)
0 4 23,766 (17/13) 6.761024 0.89 (0.72–1.19)
0 5 19,572 (14/8) 6.161024 0.69 (0.42–1.12)
75 4 16,766 (12/12) 1.461023 1.37 (0.96–2.05)
75 5 11,899 (9/8) 1.961023 2.34 (1.76–3.06)
100 4 13,980 (10/10) 1.861023 2.07 (1.75–2.44)
aThe populations analyzed correspond to the infections at an initial MOI of 1 to 2 TCID50/cell described in Fig. 3a. Passage 5 in the infections with 100 mM Rib did not
yield sufficient HCV RNA for analysis.The genomic residues analyzed are 6269 to 7666 of the NS5A-coding region. The HCV genome residue numbering corresponds to
the JFH-1 genome (accession number #AB047639).
bThe parenthesis indicates the number of clones analyzed, followed by the number of haplotypes (number of different RNA sequences); some clones did not contain
the full length sequence; when the alignment of the sequenced region was correct such clones were entered in the calculation.
cMutation frequency and nucleotide diversity are defined in Table 1 legend and Materials and Methods. Mutation types are summarized in Fig. 4b and their position in
the HCV genome and deduced amino acid substitutions are given in Table S4.
doi:10.1371/journal.pone.0071039.t002
Table 3. Ultra-deep pyrosequencing analysis of hepatitis C virus populations passaged in the absence or presence of ribavirina.
NS5A ampliconb
Parameter
Ribavirin
conc. (mM)a A1 A2 A3 A4 A5 A6
(6152–6454) (6446–6767) (6737–6954) (6910–7252) (7224–7550) (7432–7725)
Number of 0 3 7 5 15 4 7
different mutations 75 18 25 15 35 22 24
Number of 0 3 7 5 14 4 6
polymorfic sites 75 18 24 15 34 21 24
Number of 0 4 (3/0) 8 (7/0) 6 (5/0) 16 (12/3) 4 (2/1) 8 (6/1)
haplotypesc 75 18 (15/2) 26 (24/1) 16 (14/1) 35 (31/3) 22 (19/2) 25 (21/3)
[(GRA)+(CRU)]d 0 2 (2/1) 0 (0/6) 0.25 (1/4) 0.50 (4/8) 1 (1/1) 0.33 (1/3)
[(ARG)+(URC)] 75 3.5 (28/8) 2.83 (17/6) 6.5 (13/2) 1.45 (16/11) 13 (13/1) 3.75 (15/4)
aThe populations analyzed correspond to the infections at an initial MOI of 1 to 2 TCID50/cell described in Fig. 3a.
bThe HCV genome residue numbering corresponds to the JFH-1 genome (accession number #AB047639). Amplicon (A) length ranged between 216 and 339
nucleotides. The number of nucleotides sequenced was 2.16106 to 3.36106, and the number of reads on which the parameters were calculated was 10,000 for each
amplicon. Procedures are described in Materials and Methods.
cIn parenthesis the number of haplotypes with one and two mutations is given.
dIn parenthesis the two terms of the ratio are given. Mutation types are summarized in Fig. 4c and their position in the HCV genome and deduced amino acid
substitutions are given in Table S5.
doi:10.1371/journal.pone.0071039.t003
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molecular chaperon HSP90, which plays a critical role in HCV
NS5B phosphorylation [126]. Thus, formation and activity of
protein complexes involved in HCV replication may be more
sensitive than mutagenesis to nucleotide pool imbalances. It
cannot be excluded, however, that mycophenolic acid displays
some anti-HCV activity other than the one derived from
inhibition of IMPDH.
The addition of guanosine does not have the same effect on
different viruses replicating in the presence of Rib. In a persistent
infection of FMDV in BHK-21 cells, guanosine partially reversed
the antiviral but not the mutagenic activity of Rib, but it
compensated a modest mutagenic activity induced by mycophe-
nolic acid [35]. Guanosine greatly abolished the inhibition of
LCMV progeny production evoked by ribavirin or mycophenolic
acid [61], and it reversed the non-mutagenic inhibitory effect of
Rib exerted on porcine nidoviruses [63]. These differences may lie
in the viral polymerases (or their replication complexes) which
might vary in affinity for RTP and in misincorporations under
biased nucleotide concentrations, as well as in metabolic cell
alterations associated with the infection. The types of mutations
evoked by Rib, as well as the proportion of the nucleotides found
at the 59 side (22% A, 26% G, 8% U, and 44% C) and 39side (18%
A, 31% G, 12% U, 39% C) of the mutation site in the NS5A
region – values that mirror approximately the base composition of
this genomic region – render unlikely the participation of the
known ADAR activities on Rib-induced mutagenesis [127,128].
The documented mutagenic activity of Rib on HCV opens the
way to pursuing research on alternative anti-HCV protocols
[49,95–97], and such experiments are now in progress. A related
issue is to what extent Rib mutagenesis participates in the benefits
of SOC. One argument against a mutagenic activity of Rib during
therapy is that the intracellular hepatic levels of Rib are unlikely to
reach those used in cell culture (50 mM to 100 mM, which are 3- to
100-fold higher than those considered achievable during therapy in
vivo [129]). It must be considered, however, that a broad range of
Rib concentrations in human serum and in organs targeted by Rib
has been reported [130–137]. Moreover, neither the effective RTP
concentration in liver cells and at the membrane-bound HCV
replication complexes, nor RMP and RDP levels – which would
be informative of the potential activities of Rib metabolites during
SOC – have been measured. Therefore, it is not possible to relate
results in hepatoma cells in culture with those in vivo either to
support or to dismiss a mutagenic activity of Rib on HCV in vivo.
Several possibilities can account for conflicting results regarding
the mutagenic character of Rib for HCV: (i) A limited number of
HCV RNA replication rounds in the presence of Rib may be
insufficient to detect an increase in mutant spectrum complexity.
We have tested this possibility by carrying out a mutant spectrum
analysis of HCV after a single infection of 46106 Huh-7.5 reporter
cells with HCVp0 at a MOI of 0.2 TCID50/cell and 50 mM Rib
and 100 mM Rib. Neither the increase in mutation frequency nor
that of GRA and CRU transitions reached statistical significance
(A.M. Ortega-Prieto et al., unpublished results). (ii) Rib can
produce transient expansions of mutant spectrum complexity
[102,138], so that a mutational activity might be missed depending
on the time of sampling of the mutant spectrum. (iii) If
quantifications of template HCV RNA are not performed prior
to RT-PCR amplifications intended for molecular cloning and
Sanger sequencing or for UDPS, the repertoire of genomes
screened might not reflect the repertoire present in the natural
Figure 5. The effect of ribavirin (Rib) and guanosine (Gua) on HCV infectious progeny production and intracellular viral RNA and
nucleotide pools. (a) Huh-7.5 reporter cells were infected with HCVp0 at a initial MOI of 0.1–0.2 TCID50/cell, in the absence or presence of the Rib
and Gua concentrations indicated in the upper box. Infections with HCV GNN were carried out in parallel (negative control). The progeny form each
infection was used to infect fresh cells, as described in Materials and Methods. Viral infectivity was determined in the cell culture supernatant (upper
panels), and viral RNA quantitative RT-PCR in an extract of infected cells (lower panels). The discontinuous lines parallel to the abscissa indicates the
limits of detection of infectivity and viral RNA. Below, RT-PCR amplification bands using a highly sensitive HCV-specific amplification protocol that
yields a 539 bp fragment, using as template total intracellular RNA from the infection series and passage numbers indicated at the top of the
corresponding lanes; +, 2: presence or absence of amplification band. (b) Intracellular amount of GTP and RTP in Huh-7.5 reporter cells following 8 h
or 72 h of exposure to the indicated amounts of Rib. (c) Left: intracellular amount of the four nucleoside-triphosphates, following 72 h of exposure to
either Rib or Gua, as indicated at the bottom. Right: decrease or increase of nucleotide concentration as a result of exposure to Gua or Rib; note that
the maximum decrease possible is 100%. Procedures are described in Materials and Methods.
doi:10.1371/journal.pone.0071039.g005
Table 4. Quasispecies analysis of HCVp0 populations passaged in the absence or presence of ribavirin and guanosinea.
Ribavirin
conc. (mM)a
Guanosine
conc. (mM)a
Number of nt analyzed
(clones/haplotypes)b
Mutation
frequencyc
Nucleotide
diversityc p.
103 (95% CI)
0 0 29,704 (22/18) 7.761024 1.16 (0.93–1.51)
0 200 30,493 (24/17) 8.561024 1.36 (1.09–1.68)
50 0 23,766 (17/17) 1.461023 1.54 (1.16–2.11)
50 200 35,979 (27/17) 9.261024 1.39 (1.17–1.72)
100 0 21,396 (20/20) 2.061023 2.43 (1.99–3.44)
100 200 38,125 (28/26) 1.761023 2.36 (2.04–2.79)
aThe populations analyzed correspond to the infections at an initial MOI of 0.1 to 0.2 TCID50/cell described in Fig. 5a. About 25% to 50% of clones analyzed did not
contain the full length sequence expected from the primers used; when the alignment of the sequenced region was correct such clones were entered in the calculation.
The HCV genome residue numbering corresponds to the JFH-1 genome (accession number #AB047639). The NS5A-coding region (nucleotides 6269 to 7666) was
analyzed.
bThe parenthesis indicates the number of clones analyzed, followed by the number of haplotypes (number of different RNA sequences); some clones did not contain
the full length sequence; when the alignment of the sequenced region was correct such clones were entered in the calculation.
cMutation frequency and nucleotide diversity are defined in Table 1 legend and Materials and Methods. Mutation types are summarized in Fig. 4d and their position in
the HCV genome and deduced amino acid substitutions are given in Table S6.
doi:10.1371/journal.pone.0071039.t004
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sample. Both, molecular cloning and sequencing and deep-
sequencing methods are only sampling methods to approach the
complex reality of a viral mutant spectrum. Low viral loads such as
those produced by Rib will tend to underestimate the mutant
spectrum complexity unless the amounts of template are
normalized prior to RT-PCR amplification. (iv) In combination
therapies, the interplay between an inhibitor and a mutagenic
agent may affect the timing in which an increase in mutant
spectrum complexity can be observed [95,96]. It may be
significant that evidence of a mutagenic activity in vivo has been
obtained during Rib monotherapy [77]. These possible sources of
bias apply to determinations of mutant spectrum complexity both
in cell culture and in vivo, and should be evaluated in comparing
results from different studies.
An analysis of the molecular events that underlie the transition
towards HCV extinction has indicated an apparently stochastic
persistence of HCV RNA despite loss of HCV infectivity. There
have been clinical descriptions of presence of HCV RNA in
patients displaying a sustained response to treatment [139–141].
The nature of this persistent HCV RNA in hepatocytes has not
been studied, but its presence cannot be dismissed because it might
correspond to defective HCV RNAs. A class of defective viral
genomes termed defectors participate in lethal mutagenesis and
result in loss of infectivity preceding loss of viral RNA [42,114].
The possible involvement of lethal defectors in HCV extinction
and the biological significance of HCV RNA remnants following
an effective treatment deserve further investigation.
Materials and Methods
Cells and viruses
The origin of Huh 7.5, Huh 7-Lunet, Huh-7.5 reporter cell lines
and procedures for cell growth in Dulbecco’s modification of
Eagle’s medium (DMEM), have been previously described
[142,143]. Infected and uninfected cells were cultured at 37uC
and 5% CO2. The viruses used in the experiments are HCVcc
[Jc1FLAG2(p7-nsGluc2A)] (a chimera of J6 and JFH-1 from
genotype 2a) and GNN [GNNFLAG2(p7-nsGluc2A)] (carrying a
mutation in the NS5B RNA-dependent RNA polymerase render-
ing it replication-defective) [144]. To control for the absence of
contamination the supernatants of mock-infected cells maintained
in parallel with the infected cultures were titrated; no infectivity in
the mock-infected cultures was detected in any of the experiments.
Production of viral progeny and titration of infectivity
The procedures used to prepare the initial virus stock HCVp0
and for serial infections of the hepatoma Huh-7.5 cells have been
previously described [12]. Briefly, Huh-7-Lunet cells were
electroporated with 10 mg of the infectious transcript of HCVcc
(Jc1 or the negative control GNN) (260 volts, 950 mF). Electro-
porated cells were then passaged every 3–4 days without allowing
the cells to become confluent, passages were continued until
30 days post-electroporation, and the cell culture supernatants
were pooled. The virus was then concentrated 20 times using
10,000 MWCO spin columns (Millipore) as instructed by the
manufacturer, and stored in aliquots (at 270uC). To increase virus
infectivity, Huh-7.5 reporter cells were infected with concentrated
virus stocks at a MOI of 0.5 TCID50/cell, and the cells were
passaged to obtain the working viral stock HCVp0 [12]. For
titration of HCV infectivity, serially diluted cell culture superna-
tants were applied to Huh-7.5 cells and 3 days post-infection the
cells were washed with PBS, fixed with ice-cold methanol, and
stained using anti-NS5A monoclonal antibody 9E10, as previously
described [12,145].
Figure 6. The effect of mycophenolic acid (MPA) and guanosine (Gua) on HCV infectious progeny production and intracellular
nucleotide pools. (a) Huh-7.5 reporter cells were infected with HCVp0 at an initial MOI of 0.1–0.2 TCID50/cell, in the absence or presence of the MPA
and Gua concentrations indicated in the upper box. Infections with HCV GNN were carried out in parallel (negative control). The progeny form each
infection was used to infect fresh cells, as described in Materials and Methods. Viral infectivity was determined in the cell culture supernatant (upper
panels), and viral RNA quantitative RT-PCR in an extract of infected cells (lower panels). The discontinuous lines parallel to the abscissa indicates the
limits of detection of infectivity and viral RNA. Below, RT-PCR amplification bands using a highly sensitive HCV-specific amplification protocol that
yields a 539 bp fragment, using as template total intracellular RNA from the infection series and passage numbers indicated at the top of the
corresponding lanes; +, 2: presence or absence of amplification band. (b) Left: Intracellular amount of the four nucleoside-triphosphates, following
72 h of exposure to either MPA or Gua, as indicated at the bottom. Right: decrease or increase of nucleotide concentration as a result of exposure to
Gua or MPA; note that the maximum decrease possible is 100%. Procedures are described in Materials and Methods.
doi:10.1371/journal.pone.0071039.g006
Table 5. Quasispecies analysis of HCVp0 populations passaged in the absence or presence of mycophenolic acid and guanosinea.
Mycophenolic
acid conc. (mM)a
Guanosine
conc. (mM)a
Number of nt analyzed
(clones/haplotypes)b
Mutation
frequencyc
Nucleotide
diversityc
p. 103 (95% CI)
0 0 29,704 (22/18) 7.761024 1.16 (0.93–1.51)
0 200 30,493 (24/17) 8.561024 1.36 (1.09–1.68)
5 0 27,214 (23/15) 9.661024 1.11 (0.81–1.67)
5 200 23,766 (17/12) 1.161023 1.57 (0.90–2.45)
aThe populations analyzed correspond to passage 3 (except MPA for 5 mM which is passage 2 because at passage 3 the amount of HCV RNA template was insufficient
for the analysis) of infections at an initial MOI of 0.1–0.2 TCID50/cell described in Fig. 6a. The analyses for the control passages in the absence of mycophenolic acid are
the same reported in Table 4. They are included here to facilitate comparisons. The HCV genome residue numbering corresponds to the JFH-1 genome (accession
number #AB047639). The NS5A-coding region (nucleotides 6269 to 7666) was analyzed.
bThe parenthesis indicates the number of clones analyzed, followed by the number of haplotypes (number of different RNA sequences); some clones did not contain
the full length sequence; when the alignment of the sequenced region was correct such clones were entered in the calculation.
cMutation frequency and nucleotide diversity are defined in Table 1 legend and Materials and Methods. Mutation types are summarized in Fig. 4d and their position in
the HCV genome and deduced amino acid substitutions are given in Table S7.
doi:10.1371/journal.pone.0071039.t005
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Treatment with ribavirin, guanosine and mycophenolic
acid
Solutions of Rib (Sigma), guanosine (Sigma) and mycophenolic
acid (Sigma) were prepared at concentrations of 100 mM, 200 mM
and 50 mg/ml in PBS, DMEM and methanol, respectively. They
were sterilized by filtration, and stored at –70uC. Prior to use, the
stock solutions were diluted in DMEM to reach the desired
concentration. Huh-7.5 reporter cells were pretreated with the
appropriate drug concentrations during 16 h prior to infection.
Then, 46106 cells were infected with 86105 TCID50 of HCVp0;
the adsorption time was 5 h, and the infection continued for 72 to
96 h in the presence of Rib. For successive viral passages, 46106
Huh-7.5 reporter cells were infected with 2.5 ml of the superna-
tant from the previous infection; the MOI ranged between 0.1 and
1024 TCID50/cell; each MOI can be calculated from the
infectivity values given for each experiment. In some cases the
initial MOI was 1 to 2 TCID50/cell, as detailed in the
corresponding experiments.
Toxicity test
The CC50 of Rib, and mycophenolic acid was measured by
seeding 96-well plates with Huh-7.5 cells to 70% confluence and
exposing the cells to up to 250 mM Rib and 100 mM mycophe-
nolic acid for 72 hours. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
Figure 7. Effect of ribavirin (Rib) and mycophenolic acid (MPA) on the specific infectivity of HCV. (a) Huh-7.5 reporter cells were infected
with HCVp0 at an initial MOI of 0.1–0.2 TCID50/cell, in the absence or presence of the Rib concentrations indicated in the upper box; infection with
GNN was used as negative control. The experiment is the one shown in Fig. 3(b). At different passages, extracellular viral RNA was measured by
quantitative RT-PCR (left panel). Specific infectivities (right panel) were calculated with the infectivities given in Fig. 3b and the RNA concentrations
indicated in the left panel. The discontinuous horizontal line indicates the limit of detection. Statistically significant differences are indicated by one
(p,0.001) or two (p,0.0001) asterisks (one way analysis of variance as detailed in Materials Methods). (b) Infections as in (a), in the absence or
presence of MPA concentrations indicated in the boxes above the panels. The experiment is the one shown in Fig. 5(a). At different passages,
extracellular viral RNA was measured by quantitative RT-PCR (left panel). Specific infectivities (right panel) were calculated with the infectivities given
in Fig. 5(a) and the RNA concentrations indicated in the left panel. The discontinuous horizontal line indicates the limit of detection. Differences were
not statistically significant. Procedures are described in Materials and Methods.
doi:10.1371/journal.pone.0071039.g007
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diphenyltetrazolium bromide] was added to each well at a final
concentration of 500 mg/ml; 4 h later crystals were dissolved in
100 ml of DMSO and the O.D. measured at 550 nm; 50%
cytotoxicity was calculated from four different determinations as
previously described [144].
Inhibitory concentration
The IC50 of Rib, and mycophenolic acid was calculated relative
to the untreated controls (defined as 100% infectivity), as described
previously [57]; determinations were carried out in triplicate.
Nucleotide pool analysis
The procedure used has been previously described [146,147].
Huh-7.5 cells (26106 cells) either untreated or treated with the
drugs indicated for each experiment were washed with PBS and
incubated on ice for 10 min with 900 ml of 0.6 M trichloroacetic
acid. A precooled mixture of 720 ml of UvasolH (1,1,2-trichlorotri-
fluoroethane, Sigma) and 180 ml of Tri-n-octylamine (Sigma) was
added to 900 ml of the supernatant, vortexed for 10 s and
centrifuged 30 s at 12,000 g at 4uC and stored at 280uC until
further analysis. Nucleotides were separated in a Partisil 10 SAX
analytical column (4.6 mm6250 mm) (Whatman) with a Partisil
10 SAX guard cartridge column (4.6630 mm) (Capital HPLC).
Each sample (100 ml) was injected into an Alliance 2695 HPLC
system connected to a 2996 photodiode array detector (Waters);
the eluent flow rate was 0.8 ml/min, and the nucleotides were
detected at a wavelength of 254 nm, except Rib that was detected
at 220 nm. Prior to injections, the column was equilibrated with
60 ml of 7 mM NH4H2PO4, pH 3.8 (buffer A). The separation
program started with 22.5 min of an isocratic period with buffer A
followed by a linear gradient of 112.5 min to the high
concentration buffer 250 mM NH4H2PO4, 500 mM KCl,
pH 4.5 (buffer B) and a final isocratic period of 37.5 min with
buffer B. Prior to sample analysis, 50 ml of 20 pmol/ml UTP, CTP,
ATP and GTP, and 80 pmol/ml Ribavirin (Jena Bioscience), were
separated to create a processing method using the Waters
EmpowerTM Chromatography Data Software. Determinations
were carried out with two independent biological samples, each
one in triplicate. The amount of each nucleotide in cell extracts
was normalised relative to the number of cells.
RNA extraction, cDNA synthesis, PCR amplification and
nucleotide sequencing
Intracellular viral RNA was extracted from infected cells using
the Qiagen RNeasy kit according to the manufacturer’s instruc-
tions (Qiagen, Valencia, CA, USA). RT-PCR amplification was
carried out using AccuScript (Agilent), as specified by the
manufacturers. Several genomic regions were amplified using
specific oligonucleotides as primers (Table S8). Nucleotide se-
quences of genomic HCV RNA were determined using the 23 ABI
3730XLS sequencer. To evaluate the complexity of mutant
spectra, HCV RNA was extracted as described above and
subjected to RT-PCR to amplify the E2-, NS5A- and NS5B-
coding regions as previously described [12]. Amplification
products were analyzed by agarose gel electrophoresis using
HindIII-digested F-29 DNA as molar mass standards. Negative
controls (amplifications in the absence of RNA) were included in
parallel to ascertain absence of contamination by template nucleic
acids. To ensure an excess of template in the RT-PCR
amplifications for quasispecies analysis, and to avoid complexity
biases due to redundant amplifications of the same initial RNA
templates, amplifications were carried out with template prepara-
tions diluted 1:10, 1:100 and 1:1000; only when the 1:100 diluted
template produced a visible DNA band was molecular cloning
pursued using the DNA amplified from undiluted template [35].
Controls to ascertain that mutation frequencies were not affected
by the basal error rate during amplification have been previously
described [148].
For the UDPS analysis (GS-FLX platform, 454 Life Sciences-
Roche), RT-PCR was performed using Accuscript (Agilent). To
cover the complete NS5A region, and considering that the GS-
FLX Titanium chemistry allows sequencing fragments of 400–500
nucleotides, this genomic region was divided into six overlapping
amplicons, and amplification products obtained using specific
primers (Table S8). To minimize the errors due to PCR reactions,
RT-PCR amplifications were performed in triplicate and mixed
equimolarly prior to the analysis. Then, PCR products were
purified (Ampure Beads), quantified (Pico Green Assay), and
analyzed for quality (Bioanalyzer) prior to the UDPS procedure.
Negative controls (without template RNA) were run in parallel to
ascertain absence of contamination with undesired templates.
Data analysis was based on the fasta files obtained from the 454
GS system software which includes quality controls to guarantee
the integrity of the amplicons. Data processing was done on the
open source R environment [149], using Bioconductor [150] and
the Biostrings library [151] for pattern matching, sequence
alignment and functions developed for this purpose. Two levels
of errors were considered: a background level of noise that affected
both strands, and at a higher level which was neighborhood and
structure-dependent, and therefore strand-specific. For reads data
processing a demultiplexing step where the reads were assigned to
samples and amplicons was followed by a quality filter and repair
step, and by the intersection of haplotypes in the forward and
reverse strands, and an abundance filter for these consensus
haplotypes above 0.25% [152]. Accuracy validations were
performed using published procedures [150,153–155]; the same
conclusions on Rib mutagenesis were obtained with a cut-off value
of 1.0%.
Population complexity
Population complexity was measured by determining mutation
frequency, number of polymorphic sites and haplotypes as
described in the corresponding tables. Nucleotide diversity (p)
(average number of nucleotide differences per site between any
two RNA sequences of the same mutant spectrum and genomic
region) was calculated according to the formula p= n (n21)/2 Sij
pij (i,j) where n is the number of clones, and pij is the number of
different nucleotides between the pair of sequences ij divided by
the sequence length in nucleotides [156]. Confidence intervals for
nucleotide diversities were calculated using bias-corrected boot-
strap resampling method.
Statistical analyses
The statistical significance of differences between mutation
frequencies or repertoires of mutation types was evaluated by the
chi-square test (x2 test). To determine the significance of increases
of nucleotide diversity associated with drug treatments, permuta-
tion tests were carried out on the regression slope of nucleotide
diversity as a function of drug concentration, with 10,000
permutations per test. Briefly, sequences were randomly assigned
to one of the possible groups, keeping the group size as in the
sample under analysis. For each permutation, a linear regression
of the nucleotide diversity versus drug concentration was obtained,
and the value of the slope was stored. In this manner, the
distribution of the regression slope was obtained for the case in
which differences in nucleotide diversity were due solely to
random sampling. Then, a p-value for the observed slope was
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calculated as the number of times that an equal or higher slope
than the observed was found in the null distribution divided by the
number of permutations. Both, p-values from permutations tests
and bias-corrected bootstrap confidence intervals were obtained
using ad hoc scripts developed for MATLABH (code available
upon request).
To probe statistical significance of the differences in specific
infectivity, one-way analysis of the variance was performed with
statistical package SPSS 13.0 (SPSS, Inc.). For multiple compar-
isons, Bonferroni’s correction was applied. The data are presented
as mean values and standard deviations.
Quantification of HCV RNA
Real time quantitative RT-PCR was carried out using the Light
Cycler RNA Master SYBR Green I kit (Roche), according to the
manufacturer’s instructions, as previously described [157]. The 59-
UTR non-coding region of the HCV genome was amplified using
as primers oligonucleotide HCV-5UTR-F2 (59- TGAGGAAC-
TACTGTCTTCACGCAGAAAG; sense orientation; the 59
nucleotide corresponds to genomic residue 47), and oligonucleo-
tide HCV-5UTR-R2 (59- TGCTCATGGTGCACGGTCTAC-
GAG; antisense orientation; the 59 nucleotide corresponds to
genomic residue 347). Quantification was relative to a standard
curve obtained with known amounts of HCV RNA, synthesized
by in vitro transcription of plasmid GNN DNA. The specificity of
the reaction was monitored by determining the denaturation curve
of the amplified DNAs. Negative controls (without template RNA
and RNA from mock-infected cells) were run in parallel with each
amplification reaction, to ascertain absence of contamination with
undesired templates.
Assessment of HCV extinction
We have taken as criteria to consider HCV extinct those
previously described for lethal mutagenesis of FMDV [48,49].
HCV was considered extinct when no virus infectivity was
detected and no viral RNA was amplified using a sensitive RT-
PCR amplification protocol, either from the supernatant of the cell
culture that contains the putatively extinguished virus, or following
3 blind passages of the cell culture supernatants using Huh-7.5
reporter cells in the absence of any drug. The highly sensitive RT-
PCR consists in the amplification using the primers JC1-NS5A F1
and JC1-NS5A R1 (Table S8). It should be noted that infectivity
below the level of detection did not necessarily imply extinction
according to these criteria, and this is indicated in the
corresponding results.
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